Kevin Balthaser

Insider Reports History

Entity
Individual
Location
C/O Aclaris Therapeutics, Inc., 701 Lee Road, Suite 103, Wayne, PA
Signature
/s/ Matthew Rothman, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Kevin Balthaser:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Aclaris Therapeutics, Inc. Chief Financial Officer Common Stock 92.6K $184K $1.99 Mar 1, 2025 Direct
Aclaris Therapeutics, Inc. Chief Financial Officer Restricted Stock Units 2.38K $4.73K $1.99 Mar 1, 2025 Direct
Aclaris Therapeutics, Inc. Chief Financial Officer Employee Stock Option (Right to Buy) 308K Feb 3, 2025 Direct

Insider Reports Filed by Kevin Balthaser

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ACRS Aclaris Therapeutics, Inc. Mar 1, 2025 5 -$1.45K 4 Mar 4, 2025 Chief Financial Officer
ACRS Aclaris Therapeutics, Inc. Feb 1, 2025 5 -$14.4K 4 Feb 4, 2025 Chief Financial Officer
ACRS Aclaris Therapeutics, Inc. Dec 31, 2024 10 -$94.8K 4 Jan 3, 2025 Chief Financial Officer
ACRS Aclaris Therapeutics, Inc. Sep 1, 2024 3 -$337 4 Sep 4, 2024 Chief Financial Officer
ACRS Aclaris Therapeutics, Inc. Mar 1, 2024 9 -$1.76K 4 Mar 5, 2024 Chief Financial Officer
ACRS Aclaris Therapeutics, Inc. Feb 1, 2024 3 $0 4 Feb 5, 2024 Chief Financial Officer
ACRS Aclaris Therapeutics, Inc. Jan 1, 2024 3 -$2.66K 4 Jan 3, 2024 Chief Financial Officer
ACRS Aclaris Therapeutics, Inc. Sep 6, 2023 1 $75K 4 Sep 7, 2023 Chief Financial Officer
ACRS Aclaris Therapeutics, Inc. Sep 1, 2023 3 -$2.25K 4 Sep 5, 2023 Chief Financial Officer
ACRS Aclaris Therapeutics, Inc. Mar 1, 2023 10 -$23.6K 4 Mar 3, 2023 Chief Financial Officer
ACRS Aclaris Therapeutics, Inc. Feb 1, 2023 2 $0 4 Feb 3, 2023 Chief Financial Officer
ACRS Aclaris Therapeutics, Inc. Jan 1, 2023 0 $0 3 Jan 6, 2023 Chief Financial Officer